Group 1 - The company announced a share reduction plan involving shareholders Junlian Xinkang and Gao Shen, who intend to reduce their holdings by up to 2,581,774 shares, representing a maximum of 1.92% of the total share capital [1] - The reduction will occur through two methods: a maximum of 1,346,574 shares (1% of total shares) via centralized bidding and 1,235,200 shares (0.92% of total shares) through block trading, both within three months after the disclosure of the plan [1] - As of October 13, 2025, the shareholders have completed the reduction plan, having sold the full 2,581,774 shares, which is 1.92% of the company's total share capital [1] Group 2 - For the year 2024, the company's revenue composition indicates that 99.73% comes from medical devices, while other businesses contribute only 0.27% [2] - The current market capitalization of the company is 6.5 billion yuan [3]
澳华内镜：股东君联欣康和高燊已累计减持约258万股，减持计划实施完毕